bdovman@cooley.com
Brett Dovman represents both public and privately held companies in a wide range of corporate and securities matters, including private financings, M&A, public offerings and corporate governance matters.
Download full bio
Ambrx Biopharma – $126 Million IPO
MannKind – $200 Million Convertible Notes Offering
Silverback Therapeutics– $278 Million IPO
Kronos Bio – $288 million IPO
Cooley advises Ascus Biosciences on $46M Series B Round
Emerging Companies
Public Companies
Mergers & Acquisitions
Benjamin N. Cardozo School of Law Yeshiva UniversityJD, magna cum laude, Law Review, 2016
Pace UniversityMBA, 2009
Syracuse UniversityBS, Aerospace Engineering2006
New York
California
+1 858 550 6192
Locations